234
W. Yang et al. / Journal of Photochemistry and Photobiology A: Chemistry 222 (2011) 228–235
2 g/mL. At concentration of 5 g/mL, Y1 presents only 3.9% cell
viability under irradiation.
[7] M. Khurana, H.A. Collins, A. Karotki, H.L. Anderson, D.T. Cramb, B.C. Wilson,
Quantitative in vitro demonstration of two-photon photodynamic therapy
using photofrin and visudyne, Photochem. Photobiol. 83 (2007) 1441–1448.
[8] J.R. Starkey, A.K. Rebane, M.A. Drobizhev, F.-Q. Meng, A.-J. Gong, A. Elliott,
K. McInnerney, C.W. Spangler, New two-photon activated photodynamic
therapy sensitizers induce xenograft tumor regressions after near-IR laser
treatment through the body of the host mouse, Clin. Cancer Res. 14 (2008)
6564–6573.
[9] N. Cauchon, H.J. Tian, R. Langlois, Structure–photodynamic activity relation-
ships of substituted zinc trisulfophthalocyanines, Bioconjugate Chem. 16
(2005) 80–89.
[10] B.W. Henderson, D.A. Bellnier, W.R. Greco, A. Sharma, R.K. Pandey, L.A. Vaughan,
K.R. Weishaupt, T.J. Dougherty, An in vivo quantitative structure–activity
The strong PDT activity of Y1 should be due to its proper
water–lipid amphiphilicity because it is the only amphiphilic dye
among four dyes. For their lack of lipophilicity, Y2–Y4 cannot be
efficiently absorbed by tumor cells. The result confirms the great
importance of amphiphilicity for PDT dyes. Though the dynamic
range of Y1 is limited (2.5–25 g/mL), it shows remarkable PDT
efficiency compare to other three dyes. If the photosensitizer’s dose
is properly chosen (for example at 5 g/mL), Y1 is still a potential
candidate for PDT.
relationship for
a congeneric series of pyropheophorbide derivatives
as photosensitizers for photodynamic therapy, Cancer Res. 57 (1997)
4000–4007.
[11] H.A. Collins, M. Khurana, E.H. Moriyama, A. Mariampillai, E. Dahlstedt, M. Balaz,
M.K. Kuimova, D. Phillips, M. Drobizhev, A. Rebane, B.C. Wilson, H.L. Ander-
son, Blood-vessel closure using photosensitizers engineered for two-photon
excitation, Nat. Photonics 2 (2008) 420–424.
[12] E. Dahlstedt, H.A. Collins, M. Balaz, M.K. Kuimova, M. Khurana, B.C. Wilson, D.
Phillips, H.L. Anderson, One- and two-photon activated phototoxicity of conju-
gated porphyrin dimers with high two-photon absorption cross sections, Org.
Biomol. Chem. 7 (2009) 897–904.
[13] K. Ogawa, Y. Kobuke, Design of two-photon absorbing materials for molecu-
lar optical memory and photodynamic therapy, Org. Biomol. Chem. 7 (2009)
2241–2246.
[14] S.C. Boca, M. Four, A. Bonne, B. van der Sanden, S. Astilean, P.L. Baldeck,
G. Lemercier, An ethylene-glycol decorated ruthenium(II) complex for two-
photon photodynamic therapy, Chem. Commun. 30 (2009) 4590–4592.
[15] D. Belfield, M.V. Bondar, F.E. Hernandez, A.E. Masunov, I.A. Mikhailov, A.R.
Morales, O.V. Przhonska, S. Yao, Two-photon absorption properties of new
fluorene-based singlet oxygen photosensitizers, J. Phys. Chem. C 113 (2009)
4706–4711.
[16] M. Velusamy, J.Y. Shen, J.T. Lin, Y.C. Lin, C.C. Hsieh, C.H. Lai, M.L. Ho, Y.C. Chen, P.T.
Chou, J.K. Hsiao, A new series of quadrupolar type two-photon absorption chro-
mophores bearing 11, 12-dibutoxydibenzo[a,c]-phenazine bridged amines:
Their applications in two-photon fluorescence imaging and two-photon pho-
todynamic therapy, Adv. Funct. Mater. 19 (2009) 2388–2397.
[17] K. Ogawa, Y. Kobuke, Recent advances in two-photon photodynamic therapy,
Anticancer Agents Med. Chem. 8 (2008) 269–279.
[18] J. Moan, Q. Peng, An outline of the hundred-year history of PDT, Anticancer Res.
23 (2003) 3591–3600.
[19] B.W. Henderson, T.J. Dougherty, How does photodynamic therapy work, Pho-
tochem. Photobiol. 55 (1992) 145–147.
[20] J. Wu, Y.X. Zhao, X. Li, M.Q. Shi, F.P. Wu, X.Y. Fang, Multibranched benzylidene
cyclopentanone dyes with large two-photon absorption cross-sections, New J.
Chem. 30 (2006) 1098–1103.
[21] J.Q. Xue, Y.X. Zhao, J. Wu, F.P. Wu, Novel benzylidene cyclopentanone dyes
for two-photon photopolymerization, J. Photochem. Photobiol. A: Chem. 195
(2008) 261–266.
[22] J. Wu, M.Q. Shi, Y.X. Zhao, F.P. Wu, Two-photon absorption property
and photopolymerization sensitizing efficiency of asymmetrical benzylidene
cyclopentanone dyes, Dyes Pigments 76 (2008) 690–695.
[23] X.J. Wan, Y.X. Zhao, J.Q. Xue, F.P. Wu, X.Y. Fang, Water-soluble benzylidene
cyclopentanone dye for two-photon photopolymerization, J. Photochem. Pho-
tobiol. A: Chem. 202 (2009) 74–79.
[24] T. Wang, F.P. Wu, M.Q. Shi, Syntheses of novel asymmetric cyclopentanone
dyes and measurement of two-photon absorption cross-section, Chem. Res.
Chin. Univ. 19 (2003) 470–473.
[25] R.F. Kubin, A.N. Fletcher, Fluorescence quantum yields of some rhodamine dyes,
J. Lumin. 27 (1982) 455–462.
3.7. Two-photon induced cytotoxic effect
A single cell in the circular region (Fig. 5) was exposed to a
focused 800 nm laser beam. A targeted cell incubated with Y1 in
experimental group was irradiated for 1 min. The cellular edema
formed soon after treatment (Fig. 5b) and became more visible
cell. In addition, cells out of laser beam exhibited no change dur-
ing the entire process. In blank group, a targeted cell which was
treated without photosensitizers showed no significant change
after 10 min irradiation (Fig. 5e and f). It was confirmed that both
laser and photosensitizer were indispensable to exert a cytotoxic
effect on tumor cells. The results prove that the Y1 has great poten-
tial in TPE-PDT.
4. Conclusion
Through introducing carboxylate group, four water soluble ben-
zylidene cyclopentanone dyes Y1–Y4 were synthesized. Among
them, only the dye Y1 modified by one carboxylate group presented
proper water–lipid amphopathy, other three dyes had good water
solubility but lost lipophilicity. The results of EPR spectra demon-
strated that all four dyes could effectively generate ROS through
both Type I and Type II mechanisms. Their maximum ꢀ were
all above 1000 GM at 840 nm. However, only Y1 showed strong
one- and two-photon excited PDT activity to human rectal cancer
1116 cells. It was proven that introduction of carboxylate group
was a successful way to improve biocompatability of benzylidene
cyclopentanone dye but the modified degree must be controlled
within a proper range to keep its water–lipid amphipathy, which
was a very important factor to maintain the PDT activity of dyes.
Acknowledgment
[26] Z.J. Diwu, J.W. Lown, Photosensitization by anticancer agents. 12. Perylene
quinonoid pigments, a novel type of singlet oxygen sensitizer, J. Photochem.
Photobiol. A: Chem. 64 (1992) 273–287.
This work was supported by the National Natural Science Foun-
dation of China (No. 60978057).
[27] R.W. Redmond, J.N. Gamlin, A compilation of singlet oxygen yields from bio-
logically relevant molecules, Photchem. Photobiol. 70 (1999) 391–475.
[28] C. Xu, W.W. Webb, Measurement of two-photon excitation cross sections of
molecular fluorophores with data from 690 to 1050 nm, J. Opt. Soc. Am. B 13
(1996) 481–491.
[29] J. De Bruijn, F. Busser, W. Seinen, J. Hermens, Determination of octanol/water
partition coefficients for hydrophobic organic chemicals with the ‘slow-
stirring’ method, Environ. Toxicol. Chem. 8 (1989) 499–512.
[30] Y.H. Kim, J.H. Park, M. Lee, Y.H. Kim, T.G. Park, S.W. Kim, Polyethylenimine
with acid-labile linkages as a biodegradable gene carrier, J. Control. Release
103 (2005) 209–219.
[31] K.A. Zachariasse, S.I. Druzhinin, W. Bosch, R. Machinek, Intramolecular
charge transfer with the planarized 4-aminobenzonitrile 1-tert-butyl-6-
cyano-1,2,3,4-tetrahydroquinoline (NTC6), J. Am. Chem. Soc. 126 (2004)
1705–1715.
[32] T.A. Fayed, Intramolecular charge transfer and photoisomerization of 2-(p-
dimethylaminostyryl)benzoxazole: a new fluorescent probe, J. Photochem.
Photobiol. A: Chem. 121 (1999) 17–25.
References
[1] W.G. Fisher, W.P. Partridge Jr., C. Dees, E.A. Wachter, Simultaneous two-photon
activation of type-I photodynamic therapy agents, Photchem. Photobiol. 66
(1997) 141–155.
[2] K. Ogawa, H. Hasegawa, Y. Inaba, Y. Kobuke, H. Inouye, Y. Kanemitsu, E. Kohno,
T. Hirano, S. Ogura, I. Okura, Water-soluble bis(imidazolylporphyrin) self-
assemblies with large two-photon absorption cross sections as potential agents
for photodynamic therapy, J. Med. Chem. 49 (2006) 2276–2283.
[3] A. Karotki, M. Khurana, J.R. Lepock, B.C. Wilson, Simultaneous two-photon exci-
tation of photofrin in relation to photodynamic therapy, Photochem. Photobiol.
82 (2006) 443–452.
[4] I.J. MacDonald, T.J. Dougherty, Basic principles of photodynamic therapy, J.
Porphyr. Phthalocya. 5 (2001) 105–129.
[5] E.S. Nyman, P.H. Hynninen, Research advances in the use of tetrapyrrolic pho-
tosensitizers for photodynamic therapy, J. Photochem. Photobiol. B: Biol. 73
(2004) 1–28.
[33] C. Cornelissen-Gude, W. Rettig, R. Lapouyade, Photophysical properties of
squaraine derivatives: evidence for charge separation, J. Phys. Chem. A 101
(1997) 9673–9677.
[6] S.B. Brown, E.A. Brown, I. Walker, The present and future role of photodynamic
therapy in cancer treatment, Lancet Oncol. 5 (2004) 497–508.